This analysis examines the historical and forecast performance for Wyeth in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
Reasons to Purchase
Benchmark Wyeth’s performance against key rivals in the prescription pharmaceutical sector
See how Wyeth’s performance to 2013 will be hampered by the demise of four key products, cancelling out growth from a relatively promising pipeline
Learn how the company’s operating profit growth will be boosted by a strategy of continued cost containment
